SPRB logo

SPRB
Spruce Biosciences Inc

4,972
Mkt Cap
$80.31M
Volume
22,498.00
52W High
$240.00
52W Low
$4.28
PE Ratio
-1.24
SPRB Fundamentals
Price
$65.35
Prev Close
$58.53
Open
$58.78
50D MA
$66.74
Beta
1.09
Avg. Volume
53,231.86
EPS (Annual)
-$50.83
P/B
2.11
Rev/Employee
$0.00
$18.61
Loading...
Loading...
News
all
press releases
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Analysts
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given an average recommendation of "Hold" by the eight research firms that are presently covering the company...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·13d ago
News Placeholder
HC Wainwright Issues Optimistic Outlook for SPRB Earnings
Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Spruce Biosciences in a note issued to...
MarketBeat·20d ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results
Spruce Biosciences (NASDAQ:SPRB - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($9.58) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·21d ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Given New $170.00 Price Target at Citizens Jmp
Citizens Jmp lowered their price target on shares of Spruce Biosciences from $180.00 to $170.00 and set a "market outperform" rating on the stock in a research note on Tuesday...
MarketBeat·21d ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $200.00 price target on shares of Spruce Biosciences in a research report on Tuesday...
MarketBeat·21d ago
News Placeholder
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·23d ago
News Placeholder
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·23d ago
News Placeholder
Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday
Spruce Biosciences (NASDAQ:SPRB) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·27d ago
News Placeholder
Spruce Biosciences to Present at Upcoming Investor Conferences in March
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·29d ago
<
1
2
...
>

Latest SPRB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.